@article{ajmcr20221024,
author={{Koga, Takeshi and Yoshimura, Moe and Kubo, Sakiko and Nagai, Miki and Tabata, Katsuhiko and Teranishi, Hiromi and Fujino, Misato and Kawana, Hiroshi and Musha, Ikuma and Akioka, Yuko},
title={Multisystem Inflammatory Syndrome after COVID-19 Vaccination (MIS-V) Presenting with Retropharyngeal Phlegmon in a 15-year-old Boy in Japan},
journal={American Journal of Medical Case Reports},
volume={10},
number={2},
pages={35--38},
year={2022},
url={http://pubs.sciepub.com/ajmcr/10/2/4},
issn={2374-216X},
abstract={Our case report presents a young patient vaccinated for coronavirus disease 2019 (COVID-19) who developed multisystem inflammatory syndrome in children (MIS-C), which was later confirmed to be multisystem inflammatory syndrome after vaccination (MIS-V). 15-year-old boy previously infected by COVID-19 who received the first dose of COVID-19 vaccine 50 days later and developed fever, lethargy, headache, diarrhea, nausea, lip swelling, neck pain, and dysphagia. Contrast-enhanced computed tomography revealed a low absorption area with no contrast effect was observed in the posterior pharyngeal gap suggesting retropharyngeal phlegmon. He was diagnosed to be MIS-V level 2 based on the Brighton Collaboration Case Definition and improved by Intravenous immunoglobulin (IVIG). The frequency of neck symptoms in MIS-V is higher than in other febrile diseases, and many cases of retropharyngeal phlegmon are observed. In addition, pediatric COVID-19 is mostly asymptomatic or mild; therefore, it is predicted that children who are unaware of their history of COVID-19 before vaccination are not rare. Therefore, after vaccination, extra care should be required to development of MIS-V in children.},
doi={10.12691/ajmcr-10-2-4}
publisher={Science and Education Publishing}
}